4.7 Article

Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo

期刊

EUROPEAN JOURNAL OF PHARMACOLOGY
卷 698, 期 1-3, 页码 463-469

出版社

ELSEVIER
DOI: 10.1016/j.ejphar.2012.11.025

关键词

Hydrogen sulfide; Asthma; Mouse; iNOS; Glutathione peroxidase; Glutathione reductase

资金

  1. Sao Paulo Research Foundation (FAPESP), Brazil
  2. National Council for Scientific and Technological Development (CNPq)

向作者/读者索取更多资源

Recent studies show that endogenous hydrogen sulfide (H2S) Plays an anti-inflammatory role in the pathogenesis of airway inflammation. This study investigated whether exogenous H2S may counteract oxidative stress-mediated lung damage in allergic mice. Female BALB/c mice previously sensitized with ovalbumin (OVA) were treated with sodium hydrosulfide (NaHS) 30 min before OVA challenge. Forty eight hours after antigen-challenge, the mice were killed and leukocyte counting as well as nitrite plus nitrate concentrations were determined in the bronchoalveolar lavage fluid, and lung tissue was analysed for nitric oxide synthase (NOS) activity, iNOS expression, superoxide dismutase (SOD), catalase, glutathione reductase (GR) and glutathione peroxidase (GPx) activities, thiobarbituric acid reactive species and 3-nitrotyrosine containing proteins (3-NT). Pre-treatment of OVA-sensitized mice with NaHS resulted in significant reduction of both eosinophil and neutrophil migration to the lungs, and prevented the elevation of iNOS expression and activity observed in the lungs from the untreated allergic mice, although it did not affect 3-NT. NaHS treatment also abolished the increased lipid peroxidation present in the allergic mouse lungs and increased SOD, GPx and GR enzyme activities. These results show, for the first time, that the beneficial in vivo effects of the H2S-donor NaHS on allergic airway inflammation involve its inhibitory action on leukocyte recruitment and the prevention of lung damage by increasing endogenous antioxidant defenses. Thus, exogenous administration of H2S donors may be beneficial in reducing the deleterius impact of allergic pulmonary disease, and might represent an additional class of pharmacological agents for treatment of chronic pulmonary diseases. (C) 2012 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据